Copyright ©The Author(s) 2022.
World J Hepatol. Jun 27, 2022; 14(6): 1099-1110
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1099
Table 1 Studies of abnormal liver biochemistries in patients with coronavirus disease 19
Patients (n)
Wang et al[11], 202010556.2% of the patients had abnormal ALT, AST, and total bilirubin throughout the course of the diseasePatients with COVID-19 often have abnormal liver function indices
Fan et al[12], 202014837.2% had abnormal liver function at hospital admission; 14.5% out of these patients had high fever; patients with abnormal liver function had longer mean hospital stays (15.09 ± 4.79 d) than patients with normal liver function (12.76 ± 4.14 d)More than one third of SARS-CoV-2 infected patients admitted to hospitals had elevated liver function parameters, which are linked to a prolonged hospital stay
Ding et al[37], 20212,073Out of 2073 patients, 61.8% showed abnormal liver chemistries during hospitalization, and 14.3% had liver injuryCOVID-19-related mortality is predicted by abnormal levels of AST and D-Bil during admission. Infection with HBV does not raise the risk of poor COVID-19-related outcomes in patients
Cai et al[38], 202041776.3% had abnormal liver test results and 21.5% had liver injury during hospitalization.ALT, AST, total bilirubin, and gamma-glutamyl transferase levels rose to more than 3 × the upper limit of normal, respectivelyThe negative effects on liver damage are mostly due to certain drugs taken during hospitalization
Fan et al[41], 2021288Except for AST, the levels of total bilirubin and ALP in normal and severe patients varied within the normal range, with an increasing trend in critical patientsIn critical patients, COVID-19 can induce significant hepatic dysfunction, necessitating early monitoring and management. Because of their connection with disease severity in COVID-19, LDH, ALP, GGT, total bilirubin, prealbumin, and albumin may be useful for assessing and predicting disease prognosis